Literature DB >> 3663516

Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection.

J van der Lelie1, J M Lange, J J Vos, C M van Dalen, S A Danner, A E von dem Borne.   

Abstract

In persons with AIDS or at risk from AIDS, autoantibodies against platelets and granulocytes were frequently detected. Platelet-bound immunoglobulins were demonstrated by immunofluorescence in all 16 patients with AIDS, in five out of seven patients with AIDS-related complex/persistent generalized lymphadenopathy (ARC/PGL) and even in seven of 10 healthy sexually active homosexual men. Granulocyte-bound immunoglobulins were found by immunofluorescence in 12 of the 16 AIDS patients, five of the seven patients with ARC/PGL and two of the 10 symptomless men. Red cell bound immunoglobulins were not detected. All patients with AIDS and ARC/PGL and three of the symptomless men were seropositive for human immunodeficiency virus (HIV). The platelet- and granulocyte-bound immunoglobulins could be eluted in 93% and 67% of the cases, respectively. This indicates that specific autoantibodies, rather than circulating immune complexes, which were frequently increased, accounted for the findings. There was no relation between the serological findings and the platelet and granulocyte counts. We conclude that autoantibodies against platelets and granulocytes are common in patients with AIDS and those at risk.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663516     DOI: 10.1111/j.1365-2141.1987.tb02304.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Erythrocyte antibodies in AIDS are associated with mycobacteriosis and hypergammaglobulinemia.

Authors:  J R Bogner; B Gathof; B Heinrich; A Matuschke; U Bäcker; F D Goebel
Journal:  Klin Wochenschr       Date:  1990-11-09

Review 2.  Human antibodies in cancer and autoimmune disease.

Authors:  H J Ditzel
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

3.  Platelet autoantigens: identification and characterization using immunoblotting.

Authors:  D S Beardsley
Journal:  Blut       Date:  1989-07

Review 4.  Immunthrombocytopenic purpura as a model for pathogenesis and treatment of autoimmunity.

Authors:  P Imbach; J Akatsuka; V Blanchette; A Burek-Kozlowska; J Bussel; G Gaedicke; A Gianella-Borradori; E Gugler; A Hirt; B Imholz
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

5.  Clinical significance of positive direct antiglobulin test in patients with HIV infection.

Authors:  V De Angelis; C Biasinutto; P Pradella; E Vaccher; M Spina; U Tirelli
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

Review 6.  Haematological abnormalities in human immunodeficiency virus (HIV) disease.

Authors:  C Costello
Journal:  J Clin Pathol       Date:  1988-07       Impact factor: 3.411

Review 7.  Harmful and beneficial antibodies in immune thrombocytopenic purpura.

Authors:  P A Imbach
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  The serology and immunochemistry of HIV-induced platelet-bound immunoglobulin.

Authors:  R J Klaassen; J van der Lelie; A B Vlekke; H M Weigel; J K Eeftinck Schattenkerk; P Reiss; A E von dem Borne
Journal:  Blut       Date:  1989-07

9.  IgA from HIV+ haemophilic patients triggers intracellular signals coupled to the cholinergic system of the intestine.

Authors:  M E Sales; L Sterin-Borda; M M de Bracco; M Rodriguez; M Narbaitz; E Borda
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function.

Authors:  Kaku A So-Armah; Joyce Chang; Charles Alcorn; Vincent Lo Re; Jason V Baker; Russell Tracy; Adeel A Butt; Brian K Agan; David Rimland; Cynthia L Gibert; Matthew B Goetz; Krisann K Oursler; Maria C Rodriguez-Barradas; Lewis H Kuller; Sheldon T Brown; James H Stein; Melissa Skanderson; Amy C Justice; Matthew S Freiberg
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.